Patient Information Leaflet. Package leaflet: Information for the patient. Byetta 5 micrograms solution for injection in pre-filled pen. Byetta 10 micrograms solution . Learn about BYETTA, the BYETTA Pen. in patients with prior severe hypersensitivity reactions to exenatide or to any of the product components. PRODUCT MONOGRAPH. BYETTA® exenatide injection. µg/mL. mL prefilled pen (60 doses of 5 µg/dose) and. mL prefilled pen.
|Published (Last):||8 January 2018|
|PDF File Size:||9.83 Mb|
|ePub File Size:||1.63 Mb|
|Price:||Free* [*Free Regsitration Required]|
Its use is commonly associated with gastrointestinal adverse effects, including byettta, vomiting, and diarrhea. Monitor patients on antidiabetic therapy for blood glucose control if niacin nicotinic acid is added or deleted to the medication regimen and adjust dosages as clinically warranted Magnesium Salicylate: Hyperglycemia and glycosuria have been reported.
Add BYETTA to insulin glargine as a complementary action to help improve glycemic control
Exenatide should not be used in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis. Minor Diazoxide, when administered intravenously or orally, produces a prompt dose-related increase in blood glucose level, due primarily to an inhibition of insulin release from the pancreas, and also to an extrapancreatic effect.
In some patients, hypoglycemia can be prolonged. Patient and family education regarding hypoglycemia management is crucial; the patient and patient’s family inserrt be instructed on how to recognize and manage the symptoms of hypoglycemia.
Type 2 Diabetes Medication | BYETTA® (exenatide) injection
Minor Monitor blood glucose concentrations for needed antidiabetic agent dosage adjustments in diabetic patients whenever a change in either nicotine intake or smoking status occurs. This effect may lead to hypoglycemia acutely, followed by hyperglycemia with prolonged pentamidine therapy. After acute overdose, aspirin can cause either hypo- or hyperglycemia.
Exenatide is not a substitute for insulin in patients who require insulin. If worsening of or failure to achieve adequate glycemic control occurs, consider alternative antidiabetic therapy.
Byetta (exenatide) dose, indications, adverse effects, interactions from
Call your healthcare provider right away if you have nausea, vomiting, or diarrhea that will not go away, or if you cannot take liquids by mouth.
Dehydration, dialysis, kidney transplant, renal disease, renal failure, renal impairment. The agencies have not reached any new conclusions about safety inert of the incretin mimetics, although the totality of the reviewed data provides reassurance. Artsana InsuPen 29G and 31G pen needles. According to OBRA, the use of antidiabetic medications should include monitoring e.
Taking an oral contraceptive at least 1 hour before an incretin mimetic injection should reduce the risk of an effect on contraceptive or hormonal absorption.
The potential of extended-release exenatide to induce C-cell tumors in mice has not been evaluated. Exenatide has not been found to be directly nephrotoxic in preclinical or clinical studies. Aminosalicylate sodium, Aminosalicylic acid: Moniitor blood glucose and HbA1C when these drugs are used together. Changes in glycemic control can usually be corrected through modification of hypoglycemic therapy.
Exenatide mimics the enhancement of glucose-dependent insulin secretion and other antihyperglycemic actions of incretins.
Patients taking antidiabetic agents should be closely monitored for changes in glycemic control, specifically hyperglycemia, if protease inhibitor therapy is initiated.
Based on postmarketing data BYETTA has been associated with acute pancreatitis, including fatal and non-fatal hemorrhagic or necrotizing bbyetta. Aspiration is not necessary. Major The manufacturer of insulin detemir recommends initiating therapy with insulin detemir at 10 units subcutaneously once daily when combining with a GLP-1 receptor agonist such as exenatide.
Some of these events occurred in patients receiving pharmacologic agents known to affect renal function or hydration status, such as angiotensin converting enzyme inhibitors ACE inhibitorsnonsteroidal anti-inflammatory drugs NSAIDsor diuretics.
Monitor blood glucose closely during coadministration. The concurrent use of exenatide with prandial insulin has not been studied. The dosing of antidiabetic agents may require adjustment in patients who receive metoclopramide. Systemic and inhaled corticosteroids are known to increase blood glucose and worsen glycemic control in patients taking antidiabetic agents. After injection, properly dispose of the autoinjector.
Pegvisomant increases sensitivity to insulin by lowering the activity of growth hormone, and in some patients glucose tolerance improves with treatment.
It is unknown whether extended-release exenatide causes thyroid C-cell tumors, including medullary thyroid carcinoma MTCin humans.
Limited data with exenatide in pregnant women are not sufficient to determine a drug-associated risk for major birth defects or miscarriage. Patients with diabetes mellitus taking incretin mimetics should be monitored closely for hypoglycemia if consuming green tea. In most individuals, concentrations of the regular-release injection solution Byetta are measurable for approximately 10 hours post-dose. Ensure the medicine is mixed evenly; rotate and shake or tap as directed until there is no white medicine visible on sides of the pen or syringe.
The dosing of antidiabetic agents may require adjustment and blood glucose should be closely monitored when coadministered with tegaserod. Let the autoinjector come to room temperature for approximately 15 minutes before administration.
Both first- and second-phase insulin secretion improved significantly over placebo in patients with type 2 diabetes.
Moderate Monitor patients receiving antidiabetic agents closely for worsening glycemic control when corticosteroids are instituted and for signs of hypoglycemia when corticosteroids are discontinued. Blood glucose concentrations should be closely monitored if lithium is taken by the patient. The day of weekly administration can be changed if needed, as long as the last dose was administered 3 or more days before. Minor Increased frequency of blood glucose monitoring packaage be required insedt clonidine is given with antidiabetic agents.
It is acceptable for the injections to be in the same body region but the injections should NOT be adjacent to each other.
Medicine is mixed well when it appears as an even mix that is cloudy; it is okay to see air bubbles.